US Biosimilars Enjoy A Year Of Firsts In 2021
Two Interchangeable Biosimilars And First Ophthalmic Biosimilar Approved
While US biosimilar approvals have been somewhat thin on the ground in 2021 – with multiple products seeing action delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.
